|Articles|March 8, 2022
- Pharmaceutical Executive-03-01-2022
- Volume 42
- Issue 3
Pharmaceutical Executive, March 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 3 years ago
Pressed Into Action: Measuring Pharma’s Reputation Reversalover 3 years ago
Biopharma in 2021: Big Gains, Volatile Valuesover 3 years ago
The Resilience of R&D: Pharma Posted Record Output in 2021over 3 years ago
New Age of Psychedelicsover 3 years ago
Roads Less Traveledover 3 years ago
Biopharma Stocks, M&A Sputter Amid More Headwindsover 3 years ago
Pandemic Accelerates CTV Ascent: How Pharma Can Benefitover 3 years ago
The Human Factor in Data Security Breachesover 3 years ago
Tapping the Surge in Useful Contingent Labor MarketNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
